This webinar provides a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.
Interest in liquid biopsy has escalated in recent years due to the minimally invasive sampling method, potential to overcome the challenges of tumor heterogeneity, and the potential for longitudinal monitoring of tumor burden through serial sampling. Furthermore, the growing adoption of NGS allows more labs to perform NGS liquid biopsy tests in house.
In this webinar, Dr. Tomasz Zemojtel of the Berlin Institute of Health discusses how his lab implemented Roche's Avenio ctDNA Analysis Kits for in-house clinical research testing. He will discuss:
- Utility and flexibility of liquid biopsy assays for various research applications
- Specific parts of the liquid biopsy workflow that are critical for achieving high technical performance and accurate results, such as molecular barcoding and hybrid capture technology
- Implementation strategy for liquid biopsy assays using artificial plasma samples
- Data analysis and interpretation
Lastly, Dr. Zemojtel discusses the data obtained with the Avenio assay workflow from clinical research subjects with ovarian cancer.